Cargando…
Empagliflozin Increases Short-Term Urinary Volume Output in Artificially Induced Syndrome of Inappropriate Antidiuresis
OBJECTIVE: Syndrome of inappropriate antidiuresis (SIADH) is the predominant cause of hyponatremia, but treatment options are unsatisfying. SGLT2 inhibitors increase urinary glucose excretion with concomitant osmotic diuresis. We therefore hypothesized SGLT2-inhibitors as a novel treatment for SIADH...
Autores principales: | Refardt, Julie, Winzeler, Bettina, Meienberg, Fabian, Vogt, Deborah R., Christ-Crain, Mirjam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5750511/ https://www.ncbi.nlm.nih.gov/pubmed/29422914 http://dx.doi.org/10.1155/2017/7815690 |
Ejemplares similares
-
Copeptin and its role in the diagnosis of diabetes insipidus and the syndrome of inappropriate antidiuresis
por: Refardt, Julie, et al.
Publicado: (2019) -
Copeptin is not useful as a marker of malignant disease in the syndrome of inappropriate antidiuresis
por: Winzeler, Bettina, et al.
Publicado: (2019) -
OR27-6 Effects of the SGLT2-Inhibitor Empagliflozin in Patients With Chronic Syndrome of Inadequate Antidiuresis (SIAD) - Results of a Double-Blind, Randomized, Placebo-Controlled, Crossover Trial
por: Berres, Manfred, et al.
Publicado: (2022) -
Syndrome of Inappropriate Antidiuresis: From Pathophysiology to Management
por: Warren, Annabelle M, et al.
Publicado: (2023) -
Approach to the Patient: “Utility of the Copeptin Assay”
por: Christ-Crain, Mirjam, et al.
Publicado: (2022)